Comparing the Efficacy of Pregabalin and Hydroxyzine on the Anxiety Score

NCT ID: NCT01675986

Last Updated: 2016-10-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

306 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The insertion of long-lasting intravenous device is done under local anesthesia. Currently, in the investigators hospital, no premedication is given to the patients. However, this procedure occurs in a particular emotional context related to the diagnosis of cancer or malign hemopathies.

Therefore, administration of a sedative or anxiolytic drugs before the start of the procedure can be questionable.

Hydroxyzine is the reference molecule for premedication because of its anxiolytic and anti-histaminic properties A new agent, pregabalin, shares also the same properties

The main objective of this study was to compare the efficacy of pregabalin and hydroxyzine on the anxiety score as a premedication during the insertion of long-lasting intravenous device under local anesthesia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Feeling Anxious

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregabaline

Groups PREGABALINE : 150 mg de LYRICA®

Group Type EXPERIMENTAL

Pregabalin

Intervention Type DRUG

150 mg

Hydroxyzine

Groups HYDROXYZINE : 75 mg d'ATARAX®

Group Type EXPERIMENTAL

hydroxyzine

Intervention Type DRUG

75 mg

Lactose

Groups placebo : 4 g de lactose

Group Type PLACEBO_COMPARATOR

Lactose

Intervention Type DRUG

4 g

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

hydroxyzine

75 mg

Intervention Type DRUG

Pregabalin

150 mg

Intervention Type DRUG

Lactose

4 g

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged from 18 to 75 years
* Patient schedules for insertion of long-lasting intravenous device

Exclusion Criteria

* History of previous insertion of long-lasting intravenous device or central intravenous catheter
* long term treatment of gabapentin or pregabalin
* Hypersensitivity to pregabalin or any of the excipients
* Hypersensitivity to hydroxyzine, one of its metabolites, one of the excipients, another derivative of piperazine, aminophylline or ethylene diamine.
* Patient at risk of glaucoma e
* Patient at risk for urinary retention
* Patient severe respiratory failure
* Patient at the general condition not too corrupted (ASA IV)
* Renal failure with creatinin clearance \< 30 ml / min
* Patient not affiliated to Social Security
* Pregnant or lactating
* Patients in emergency situations
* Inpatient without consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Poitiers University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bertrand DEBAENE, MD

Role: PRINCIPAL_INVESTIGATOR

Poitiers University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de POITIERS

Poitiers, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GABAPAC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pregabalin and Post-thoracotomy Pain
NCT00663962 COMPLETED PHASE4